中国医院用药评价与分析2024，Vol.24Issue(7)：862-865,870,5.DOI:10.14009/j.issn.1672-2124.2024.07.020
利伐沙班与华法林治疗非瓣膜性心房颤动的临床综合评价
Clinical Comprehensive Evaluation of Rivaroxaban and Warfarin in the Treatment of Nonvalvular Atrial Fibrillation
摘要
Abstract
OBJECTIVE:To construct the comprehensive evaluation index system of rivaroxaban for clinical comprehensive evaluation of rivaroxaban and warfarin in the treatment of nonvalvular atrial fibrillation,so as to provide evidence-based evidence for health policy formulation and clinical rational drug use.METHODS:The Delphi and Analytic Hierarchy Process were used to establish a comprehensive evaluation index system and determine the weights of each indicator.Relevant evidence data were collected through clinical observation studies,Meta-analysis,questionnaires,drug instructions,guideline consensus and official website,the experts scored rivaroxaban and warfarin in the treatment of nonvalvular atrial fibrillation according to the evidence data of safety,effectiveness,economy,suitability,accessibility and innovation.Final score of the indicator was obtained by combining the weight of the indicator and the expert score.The total score of rivaroxaban and warfarin were added together,and the total score of the two was compared.RESULTS:The constructed comprehensive evaluation system of rivaroxaban included 6 first-level indicators and 21 second-level indicators;the comprehensive evaluation score of rivaroxaban was 85.12 points,and the comprehensive evaluation score of warfarin was 71.45 points.CONCLUSIONS:The clinical comprehensive value of rivaroxaban is higher than that of warfarin in the treatment of nonvalvular atrial fibrillation,which can provide reference basis for national medical insurance policies and rational clinical medication.关键词
利伐沙班/华法林/心房颤动/临床综合评价Key words
Rivaroxaban/Warfarin/Atrial fibrillation/Clinical comprehensive evaluation分类
医药卫生引用本文复制引用
王超花,于焕君,郭瑞臣..利伐沙班与华法林治疗非瓣膜性心房颤动的临床综合评价[J].中国医院用药评价与分析,2024,24(7):862-865,870,5.基金项目
山东省卫生健康委员会-山东省第二批药品临床综合评价项目(No.2022YZ018) （No.2022YZ018）
